GSK starts Phase III study for severe asthma treatment
pharmafile | March 18, 2021 | News story | | GSK, asthma, phase III
GSK has announced today that the first patient has been dosed in part of their Phase III clinical trial investigating the safety and efficacy of GSK3511294 (GSK’294) in severe eosinophilic asthma (SEA).
The investigational medicine, GSK’294, has the potential to be the first biologic to deliver long-acting suppression of IL-5 in patients with SEA from one subcutaneous injection every six months.
Christopher Corsico, Senior Vice President Development at GSK, said: “Around 10% of all asthma patients suffer from the avoidable symptoms of severe eosinophilic asthma and only one in four patients who are eligible for a biologic therapy currently receive one. These patients might benefit from more targeted therapies to better control their condition.
“We believe GSK’294 could provide another option to these patients that build on the positive impact seen with current anti-IL5 treatments and may also offer the advantage of one subcutaneous injection every six months.”
GSK’294 is an anti-IL-5 monoclonal antibody and is a new biologic entity that has been engineered for high affinity and long-acting suppression of IL-5 function. IL-5 is the major cytokine responsible for the proliferation, activation and survival of eosinophils, making it a proven treatment target for severe asthma patients with higher levels of eosinophils.
The Phase III programme for GSK’294 involves three studies, SWIFT-1, SWIFT-2, and NIMBLE, with 2,450 patients to assess the efficacy and safety of the anti-IL-5 treatment.
The SWIFT-1 and SWIFT-2 trials will assess GSK’294 in participants with severe uncontrolled asthma with an eosinophilic phenotype, despite standard of care treatment with medium to high dose inhaled corticosteroids as well as one additional controller.
Kat Jenkins
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
1nhaler receives £1.5m in funding to develop new cardboard inhaler
1nhaler, a Scotland-based developer of drug delivery devices, has received £1.5m in seed funding for …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
